CGEN - Multiplikator P/S Compugen Limited

Compugen Ltd. bases its cancer immunotherapy developments in US and Israeli laboratories, utilizing AI for target discovery. The current P/S ratio on this GURU.Markets platform chart illustrates the business valuation dynamics, where 2.70 serves as the base parameter value. The company's progress depends on clinical success, ignoring macroeconomic cycles. Demand for innovation makes this sector a reliable defensive asset.

To minimize risks during long-term asset ownership, it is necessary to correlate the market value of a business with its actual cash flow. An analysis of the price-to-sales multiple allows for an assessment of Compugen Ltd. (CGEN) capitalization relative to annual revenue, which is critical for companies with a strong R&D core and a loyal staff of immunologists whose intellectual value is priced into future sales.